References
- Blakey DC, Westwood FR, Walker M, Hughes GD, Davis PD, Ashton SE, Ryan AJ. Antitumour activity of the novel vascular targeting agent ZD6126 in a panel of tumor models. Clinical Cancer Research 2002a; 8: 1974–1983
- Blakey DC, Ashton SE, Westwood FR, Walker M, Ryan AJ. ZD6126: A novel small molecule vascular targeting agent. International Journal of Radiation, Oncology, Biology, Physics 2002b; 54(5)1497–1502
- Davis PD, Dougherty GJ, Blakey DC, Galbraith SM, Tozer GM, Holder AL, Naylor MA, Nolan J, Stratford MRL, Chaplin DJ, Hill SA. ZD6126: A novel vascular-targeting agent that causes selective destruction of tumor vasculature. Cancer Research 2002; 62: 7247–7253
- Evelhoch JL, LoRusso PM, He Z, DelProposto Z, Polin L, Corbett TH, Langmuir P, Wheeler C, Stone A, Leadbetter J, Ryan AJ, Blakey DC, Waterton JC. Magnetic resonance imaging measurements of the response of murine and human tumors to the vascular-targeting agent ZD6126. Clinical Cancer Research 2004; 10: 3650–3657
- Goertz DE, Yu JL, Kerbel RS, Burns PN, Foster FS. High-frequency Doppler ultrasound monitors the effects of antivascular therapy on tumor blood flow. Cancer Research 2002; 62: 6371–6375
- Goto H, Yano S, Zhang H, Matsumori Y, Ogawa H, Blakey DC, Sone S. Activity of a new vascular targeting agent, ZD6126, in pulmonary metastases by human lung adenocarcinoma in nude mice. Cancer Research 2002; 62: 3711–3715
- Horsman MR, Murata R. Vascular targeting effects of ZD6126 in a C3H mouse mammary carcinoma and the enhancement of radiation response. International Journal of Radiation, Oncology, Biology, Physics 2003; 57(4)1047–1055
- Judson I, Scurr M, Roberts DW, Partridge EA, D'Souza RA, Tan S. Pharmacokinetics and metabolism of ZD6126 in patients with solid tumours (in preparation). 2007
- Lenz EM, D'Souza RA, Jordan A, King CD, Smith S, Phillips P, McCormick A, Roberts DW. HPLC-NMR with severe column overloading: Fast track metabolite identification in urine and bile samples from rat and dog treated with [14C]-ZD6126. Journal of Pharmaceutical and Biomedical Analysis 2007, (in press)
- McCarty MF, Takeda A, Stoeltzing O, Liu W, Fan F, Reinmuth N, Akagi M, Bucana C, Mansfield PF, Ryan A, Ellis LM. ZD6126 inhibits orthotopic growth and peritoneal carcinomatosis in a mouse model of human gastric cancer. British Journal of Cancer 2004; 90: 705–711
- Partridge EA, D'Souza RA, Lenz EM, Smith SM, Clarkson-Jones J, Roberts DW. Disposition and metabolism of a colchiane derivative [14C]-ZD6126 in rat and dog (in preparation). 2007
- Scurr M, Judson I, Brock C, O’Donnell A, Tan S, Partridge EA, D'Souza RA, Roberts DW. Assessment of metabolism, excretion and pharmacokinetics of a single dose of [14C]-ZD6126 in patients with solid malignant tumors [abstract]. Journal of Clinical Oncology 2004; 22(14S)3083
- Siemann DW, Rojiani AM. Enhancement of radiation therapy by the novel vascular targeting agent ZD6126. International Journal of Radiation, Oncology, Biology, Physics 2002; 53(1)164–171
- Siemann DW, Chaplin DJ, Horsman MR. Vascular-targeting therapies for treatment of malignant disease. Cancer 2004; 100(12)2491–2499
- Soltau J, Drevs J. ZD-6126 AstraZeneca. IDrugs 2004; 7(4)380–387
- Varghese HJ, MacKenzie LT, Groom AC, Ellis CG, Ryan A, MacDonald IC, Chambers AF. In vivo videomicroscopy reveals differential effects of the vascular-targeting agent ZD6126 and the anti-angiogenic agent ZD6474 on vascular function in a liver metastasis model. Angiogenesis 2004; 7: 157–164